Always a highlight of @ASTRO_org Meetings, the Awards ceremony🔥 Because we like to celebrate our community🥳
Huge shoutout to classmate, friend, role model, and mentoring force Helen Shih of MGH/MGB👏👏👏 (now she just needs to join #SoMe‼️)
#ASTRO25@DKirschMDPhD@AmyWisdom8@EmilyLebow
I was privileged to nominate Dr Helen Shih for the ASTRO Mentorship Award and thrilled to see her honored this year along side Drs Gibbs and Yahalom🌟 She’s been an incredible mentor to me since med school in 2016, shaping my path in rad onc and inspiring me to mentor others
Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTRO Mentorship awards!!
They will be recognized at #ASTRO25 in San Francisco. @StanfordRadOnc@MassGeneralNews@MSK_RadOnc
https://t.co/TIGyGv8Zfq
#ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in @NatureMedicine and on the @ASCO stage today. Abstract 102. @DrORourke2 https://t.co/1qzmYYZN66
The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient.
This award recognizes her impact on cancer care through neuroimaging and biomarker research on neurotoxicity after CAR T-cell therapy: https://t.co/5b5zyPjgXH.
#CARTcells for #DIPG#DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief.
“There’s a lot of loss that led to this research,” Drew’s dad said. “I hope those families know that this success is because of them.”
https://t.co/rNnHkL6pQR
1/2
Promising outcomes of combining #radiotherapy and durvalumab without chemo in LA-NSCLC.
PFS associated with PD-L1.
Wonder if there is a path for personalized therapy where chemo can be dropped in high PDL1?
#ASTRO24
Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the risk of symptomatic radiation necrosis for pts receiving SRS and brain metastases. ADCs included T-DXd, T-DM1, and SG. (1/n)
https://t.co/dplp1nJKmW
In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associated w/ higher risk of radiation necrosis. The absolute risk was low for small lesions, but increased rapidly w/ volume & prior RT. https://t.co/XaRdIu5e3x